Loading...

23andMe Holding Co.

MEUSW•NASDAQ
Healthcare
Medical - Diagnostics & Research
$1.38
$-0.13(-8.61%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the past four quarters, 23andMe Holding Co. demonstrated steady revenue growth, increasing from $64.03M in Q4 2023 to $60.26M in Q3 2024. Operating income reached -$35.87M in Q3 2024, maintaining a consistent -60% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$20.09M, reflecting operational efficiency. Net income rose to -$45.53M, with EPS at -$2.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;